Also known as: Rilutek; RP 54274; PK 26124
Riluzole is a pharmaceutical-grade active ingredient classified as a Glutamate Antagonist Neuroprotective Agent. Mediocon Inc supplies high-purity Riluzole API conforming to IP / BP / EP / USP specifications, manufactured in our GMP-certified facility in Aurangabad, Maharashtra, India.
Riluzole is the first and most established disease-modifying treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It works by inhibiting glutamate-mediated neurotoxicity, blocking sodium channels, and interfering with intracellular signaling cascades linked to glutamate receptor activation. Riluzole slows disease progression and extends patient survival.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Riluzole (CAS 1744-22-5) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Riluzole is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance